Adaptive Biotechnologies Reports Q3 Earnings Beat on Revenue and EPS
Adaptive Biotechnologies (ADPT) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of $0.02, surpassing estimates by $0.11, while total revenue reached $83.9 million, beating projections by $12.3 million. Driven by strong performance in its Minimal Residual Disease (MRD) business, the company has raised its full-year revenue guidance for that segment. Adaptive Biotechnologies now expects MRD revenue to fall between $276 million and $286 million, an upward revision from its previous guidance range.
Tickers: $ADPT